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Bipolar affective disorder is a serious mental disease associated with significant morbidity
and mortality. Good-quality research available to guide treatment strategies remains insuf-
ficient, particularly with regard to manic or hypomanic episodes. A critical review of the
various stages of mania might be helpful for pharmaceutical companies and investigators as
a prerequisite for the clinical evaluation of potential antimanic properties of medications.The
main difficulty is with a comparison between anticonvulsants, antipsychotics, and mood
stabilizers such as lithium (with equal efficacy in the acute phase and the prevention of
recurrent manic episodes). No consensus has been reached with regard to the treatment
of bouts of acute mania in various parts of the world. Controlled clinical trials have, at last,
provided irrefutable evidence of the activity of lithium, which has long been used alone, as
well as that of divalproate or its derivatives and, to a lesser extent, carbamazepine.The new
antipsychotic agents have more recently established their efficacy, especially aripiprazole,
asenapine, quetiapine; olanzapine, risperidone, and ziprasidone (not sure where the para-
dox is). In Europe, haloperidol is still the reference substance used in clinical trials despite
the fact that it is not officially indicated in the treatment of mania. In the USA, lithium,
divalproate, or antipsychotics can be prescribed as first-line treatment. In Europe, lithium
remains the first-line medication, whereas divalproate and atypical antipsychotic agents
are used only as second-line therapy. Although both types of medication (antipsychotics,
normothymic agents, and/or anticonvulsants) have proved to be clinically effective in the
management of mania by reducing the mania scores overall, the same does not apply,
however, to all symptoms of mania. Factorial approaches to mania have all shown that
since there are several clinical forms of mania, several clusters of manic symptoms can be
identified. Antipsychotic and normothymic agents and/or anticonvulsants do not appear to
have the same effects on each of these identifiable clusters of symptoms, mainly psychotic
features. We believe that it is vitally important for future clinical trials of mania treatment
to focus on the treatment effect by adopting a factorial approach to characterization of
the episode using an appropriate methodological structure. These questions highlight the
uncertainty shrouding the very structure of manic episodes, namely that these are pre-
dominantly of a thymic or psychotic nature. The Europeans undoubtedly consider mania
to be more of a thymic episode and prefer lithium as the first-line treatment, whereas the
Americans believe that psychotic symptoms dominate and widely prescribe antipsychotic
agents. However, from the standpoint of clinical trials currently available, even though
antipsychotic agents are certainly effective in reducing the scores on the mania scales, it
is not clear whether they can be considered purely as antimania treatments.
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INTRODUCTION
Mania and depression have been considered as distinct, yet
related, phenomena since antiquity (Angst and Marneros, 2001).
Only in recent history, mood disorders have been divided into
two distinct syndromes: mania and depression. As the father
of current psychiatric nosology, Kraepelin was one of the first
to subtype manic subjects into those with and without depres-
sion. From Kraepelin, until the second version of the Diag-
nostic and Statistical Manual of Mental Disorders (DSM-II;
American Psychiatric Association, 1968), both syndromes were
considered as mood disorders including different subtypes such
as recurrent mania, recurrent depression, recurrent mania, and
depression, and affective disorders with mixed states. Later on,
DSM-III made a distinction between major depressive disor-
der and bipolar disorder defined by the presence of mania.
Several reasons have led to consider bipolar disorder and
unipolar disorder as distinct illnesses. Furthermore, increas-
ing evidence has supported a distinct etiology and a differ-
ent lifetime course for mania (more severe) as compared to
depression.
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Mania and depression are considered as opposite poles of a con-
tinuum with grandiose self-esteem and self-perceived abilities on
one side, and feelings of self-loathing, incompetence, and apathy
on the other. These two opposite states of mood can be observed
at different periods of time in the same bipolar patient.
Bipolar patients seem to experience greater mood reactivity
to environmental circumstances as compared to controls. This
hyper reactivity may be more pronounced for positive stimuli.
Indeed, during manic episodes, bipolar subjects remember the
positive moments of their life much more readily than the neg-
ative ones, and they perceive themselves much more positively
than they would at other times. They show large increases in self-
confidence after initial successes or when they are experiencing
hypomanic symptoms. After small successes or in the presence of
mild hypomanic symptoms, subjects with a bipolar history or a
vulnerability to the disease appear to perceive their life goals as
more attainable, they are more likely to tackle difficult tasks, and
they are less likely to perceive danger. Interestingly, these processes
appear to require a trigger: bipolar subjects do not appear to exhibit
robustly elevated self-confidence in their success during euthymic
periods in the absence of recent success or positive moods. Hence,
success seems to promote greater goal pursuit among persons vul-
nerable to bipolar disorder. This may contribute to explain the
higher risk of manic symptoms after major life successes, described
above (Johnson et al., 2000). It appears also that elevated goal
pursuit predicts increase in manic episodes recurrence over time
(Lozano and Johnson, 2001). Even though bipolar subjects appear
to endorse higher than average levels of goal setting, and higher
self-confidence during mania, one might expect the distribution
of their scores to overlap with the general population. Is the asso-
ciation of permanent high goals, liability of emotional reactions,
and increased self-confidence after success sufficient to account
for the spiral into mania? Or is something else needed? Basic
research suggests that dopaminergic pathways from the nucleus
accumbens to the prefrontal cortex are activated when subjects
anticipate a reward (Knutson et al., 2001). Bipolar disorder has
been hypothesized to result from a dysregulation of this pathway
(Hestenes, 1992; Depue et al., 1996). Antipsychotic drugs have
shown a good efficacy in the treatment of mania. Hence, one might
expect that bipolar patients may have greater difficulties in achiev-
ing emotional and behavioral control which challenge the reward
system.
Since 2005, many guidelines have been published [World Fed-
eration of Societies of Biological Psychiatry (Grunze et al., 2009);
the Canadian Network for Mood and Anxiety Treatments (CAN-
MAT) and the International Society for Bipolar Disorders (Yatham
et al., 2009), the British Association for Psychopharmacology
(BAP; Goodwin and Consensus Group of the British Association
for Psychopharmacology, 2009), the National Institute for Health
and Clinical Excellence (NICE) (2009), and the Clinical Practice
Recommendation for bipolar disorder (Malhi et al., 2009)]. Nivoli
et al. (2012) have published an interesting critical review of the
existing guidelines focusing on the treatment of manic/hypomanic
and mixed episodes. They came to the conclusion that there is
a widespread inconsistency in diagnostic assessment of different
subtypes and definitions with respect to bipolar disease across
guidelines and when specific diagnostic criteria are proposed, as
in DSM IV and ICD 10, they are insufficiently representative of
the clinical complexity of the bipolar disorder patient. In the first
part of this paper we will discuss the current diagnostic criteria.
All guidelines agree that the first-line treatment of
manic/hypomanic and mixed episodes should be lithium, val-
proate, or atypical antipsychotics as monotherapy. Combination
therapy including lithium or valproate with an atypical antipsy-
chotic is suggested as a second-line choice, and sometimes as first
choice treatment in cases of severe mania. In the second part of
this paper we will discuss the different mood stabilizers and atyp-
ical antipsychotics that might be used in mania in this paper and
the limitations of the current research conducted in this field.
CLASSICAL CLINICAL DESCRIPTIONS
Manic states are typically characterized by abnormally and persis-
tently elevated, expansive, or irritable mood lasting at least 1 week
associated with different combinations of the following symptoms:
inflated self-esteem or grandiosity, subjects are more talkative than
usual or make pressure to keep talking, they speak faster, they
have flight of ideas or subjective experience that thoughts are rac-
ing, quicker thought, higher distractibility, psychomotor agitation,
higher energy (with a corresponding decreased need for sleep),
irritability, increased perceptions, excessive involvement in plea-
surable activities with a high potential of harmful consequences
(e.g., engaging in unrestrained buying sprees, sexual indiscretions,
or foolish business investments). The degree, type, and chronicity
of these cognitive, perceptual, and behavioral changes determine
the subtype of mania, namely hypomania, or mania.
In hypomania, the above changes are generally moderate and
may or may not result in serious problems for the individual expe-
riencing them. In more severe episodes, however, they profoundly
disrupt the lives of the patients, their families, and the society.
In acute mania, mood was not accurately described by the
classical authors, perhaps because extreme changes in cognition
and behavior are more easily observable than are subjective mood
states. Two thousand years ago, however, Aretaeus of Cappado-
cia noted that those who were manic were active, and expansive.
They were naturally joyous, they laughed, and they joked: “they
show off in public with crowned heads as if they were returning
victorious from the games; sometimes they laugh and dance all
day and night.” Few centuries later, Kraepelin (1921) and more
recently, Roccatagliata (1986) agreed, but have stressed the unsta-
ble presentation of manic mood: “Mood is unrestrained, merry,
exultant, occasionally visionary of pompous, but always subject
to frequent variation, easily changing to irritability and irascibil-
ity or even to lamentation and weeping.” Activity and behavior
are greatly increased and diversified in mania. Patients are tire-
less, rash, virulently opinionated, and may show aggressiveness.
For many patients, excessive energy translates directly into pres-
sured writing and an inordinate production of written declaration,
poetry, and artwork. Particularly dramatic and extreme among the
clinical features of acute mania are the frenetic, seemingly aim-
less, and occasionally violent behaviors of manic patients. In the
same way, strange, impulsive, and grossly inappropriate behavior
patterns are frequently observed.
DIAGNOSIS OF ACUTE BIPOLAR MANIA
The history of psychiatric diagnosis has been notable for its
confusion, reflected in the myriad overlapping systems used for
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classifying and subtyping depressive disorders. However, Krae-
pelin clarified the diagnosis of depression by gathering all recur-
rent affective disorders into manic-depressive illness, a broad
category later divided into unipolar and bipolar subgroups.
When making the diagnosis, the BAP guidelines suggest the
identification of core symptoms of mania as well as the importance
of second sources for collateral information (family members,
caregivers, etc.). The clinician will combine them together with
the patient’s history and previous response to treatment, as well
as the family history. Individual symptoms and even clusters of
symptoms, examined at one specific time often lack diagnostic
specificity, although such cross-sectional views are sometimes the
only ones available.
The structure of mania has been examined in recent phe-
nomenological studies using factor analytic and other methods.
These studies have revealed that the most common symptoms of
mania are motor activation, flight of ideas, pressured speech, and
decreased sleep, while elevated mood and increased sexuality are
less common. These authors have also identified four types of
mania that correspond to Kraepelin’s observations: hypomania,
acute mania, delusional mania, and depressive or anxious mania.
DSM IV DEFINITION OF A MANIC EPISODE
Criterion A: a manic episode is a distinct period during which there
is an abnormally and persistently elevated, expansive, or irritable
mood. This period of abnormal mood must last at least 1 week (or
less if the hospitalization is required).
Criterion B: the mood disturbance must be accompanied by at
least three additional symptoms from a list that includes inflated
self-esteem or grandiosity, decreased need for sleep, pressure of
speech, flight of ideas, distractibility, increased involvement in
goal-directed activity or psychomotor agitation, and excessive
involvement in pleasurable activities with a high potential for
painful consequences.
Criterion C: the symptoms do not meet criteria for a mixed
episode.
Criterion D: the disturbance must be sufficiently severe to
cause marked impairment in social or occupational functioning
or to require hospitalization, or it is characterized by presence of
psychotic features.
A manic episode can occur during different subtypes of bipolar
disorder:
– In type I, the patient presents manic episodes alternating with
major depressive episodes (Ahearn and Caroll, 1996).
– In type II, the patient presents recurrent major depressive
episodes and at least one or several hypomanic episodes
(Hantouche et al., 1998).
– In type III, the patient presents some recurrent major depres-
sive episodes with one or several pharmacologically induced
hypomanic episodes.
A particular subtype of manic episode is mania with delir-
ium or psychotic mania, where clinical symptoms of mania are
associated with mood-congruent psychotic features. Grandiose
delusions may be an expression of severity of mania whereas other
delusions might confuse the distinction from schizophrenia and
rather correspond to a distinct subtype of mania.
In mixed episode, criteria for a manic episode and a major
depressive episode (except for the duration) are fulfilled simul-
taneously, nearly every day during at least 1 week (Cassidy et al.,
2000). The mood disturbance is sufficiently severe to cause marked
impairment in occupational functioning, social activities or rela-
tionships with others, or to require hospitalization in order to
prevent harm to self or others, or the patient has some psychotic
features.
Dysphoric mania describes mania with some depressed and
dysphoric features that are either not severe enough or insuffi-
ciently lasting to fulfill the criteria for a major depressive episode.
Concerning treatment, the amount of evidence is rather limited in
psychotic mania, dysphoric mania, or mixed episodes.
INCLUSION CRITERIA FOR ACUTE BIPOLAR MANIA
A priori, only bipolar I patients may be included in clinical trials.
However, the inclusion of hypomanic subjects fulfilling type II or
III bipolar disorder criteria might be considered. We could also
include only patients with a first manic episode, but they are less
numerous, and might be sometimes difficult to differentiate from
schizo-affective patients. Schizo-affective patients might require
the use of two different scales for diagnosis and assessment SADS-
C (Endicott and Spitzer, 1978) and Young-Mania-Rating-Scale
(YMRS; Young et al., 1978).
Is it necessary to include patients presenting psychiatric co-
morbidities in clinical trials? Comorbidity is frequently observed
in bipolar patients:
– 17–35% Have a generalized anxiety disorder (GAD),
– 19% Have panic attacks,
– 9% Have obsessive compulsive disorder (OCD),
– 20% Have social anxiety disorder.
Do these co-morbidities influence the therapeutic response to a
given medication? In clinical practice, it is difficult to either include
or exclude these patients where the investigator does not necessar-
ily know the past psychiatric history. The use of the MINI could
help to distinguish between a past history of a comorbid disor-
der and current comorbid symptoms associated with the manic
episode. However, the MINI (Sheehan et al., 1998) is not suitable
for the assessment of comorbid psychotic features.
WHAT IS THE MINIMAL TREATMENT DURATION REQUIRED
FOR A CLINICAL TRIAL DURING AN ACUTE MANIC EPISODE?
In most studies, the duration of the trial is 4 weeks, and the patients
are either hospitalized or not. Although manic episodes improve
in general quickly enough, this duration does not allow distin-
guishing a simple remission from cycling patients. Rapid cyclers
(>4 cycles of depression or mania per year) have a particularly
labile mood. It is crucial to study the efficacy of a specific treat-
ment during the acute phase but also to identify potential switches
from manic episode to depression. In order to answer this ques-
tion, duration of clinical trials of 6 weeks rather than 4 may be
considered.
This 6-week-period should be followed by a maintenance phase
for another 6 weeks in order to include potential relapses. It seems
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therefore necessary to plan an overall length of 12 weeks (6 weeks
for the acute phase and 6 weeks for the maintenance phase).
In addition, long term studies are also necessary to provide
scientific data about the minimal duration of treatment required
after a manic episode (Yatham et al., 2012).
EXCLUSION CRITERIA FOR ACUTE BIPOLAR MANIA
In controlled studies, comorbid, suicidal, medically ill patients
are excluded, however, the data are lacking concerning the
management of these patients by psychiatrists.
The exclusion criteria should be as follows:
– Suicidal risk.
– First manic episode.
– Bipolar I, rapid cycling (more than 4 cycles per year).
– Patients whose manic episode started more than 4 weeks
earlier and patients with psychotic symptoms, or a manic
episode caused by substances, medications, or a general medical
condition.
– Manic symptoms caused by psychotropic drugs including
benzodiazepines used during the previous 3 months.
– Past history of delirium, schizophrenia, schizo-affective
episodes, or personality disorders according to DSM IV criteria.
The adjunctive treatments will have to be adequately reported.
It seems reasonable to exclude patients who were receiving long
half-life antidepressant treatment before inclusion such as fluox-
etine or even sertraline and patients for whom plasma concen-
trations of lithium, carbamazepine, or valproate were equal or
superior to the efficient well-known concentrations.
The adjunctive use of benzodiazepines, which have no activity
on mood, such as lorazepam and oxazepam may be necessary for
example when the duration of sleep is lower than 3–4 h.
WHICH ASSESSMENT SCALES CAN BE USED?
The YMRS is the gold standard for the evaluation of acute manic
symptoms during clinical trials.
The minimal score required for inclusion is equal or superior
to 20, however, such a score may allow inclusion of patients pre-
senting with hypomania which might introduce a bias. In order
to firmly exclude hypomanic patients, a minimum inclusion score
equal or superior to 24 seems more appropriate.
Clinical studies usually use a 50% reduction of the YMRS and
Mania rating scale (MRS) The MRS can be divided into Mania
Symptoms Scale (MSS) and Barratt Impulsiveness Scale (BIS).
The MSS allows the assessment of the core symptoms of mania
(sleep disorders, increased energy or motor activity, megalomania,
increase of finalized activities), and of the elevated mood which
is not considered as a cardinal feature of mania. The MSS score
required for inclusion should be equal or superior to 15. In case of
severe mania, it will be necessary to keep a score equal or superior
to 20, with a score superior to 5 on at least two items of this scale.
The additional use of a nurse scale would not increase the
strength of the assessment of manic symptoms.
The YMRS will be considered as the main assessment scale in
order to evaluate treatment efficacy. Clinical responders will be
defined as patients whose improvement on YMRS and MSS as
compared to baseline will be at least 50% with a score on the
Clinical Global Impression for Bipolar Disorder scale (CGI-BP)
mania lower than 4.
The Montgomery–Åsberg Depression Rating Scale (MADRS;
Montgomery and Asberg, 1979) or Hamilton Depression Rating
Scale (HAMA-D) should be used systematically in order to assess
the possible switch toward depression.
Patients with mixed episodes could be included, if they present
a YMRS score superior to 24.
WHICH DRUGS ARE OF INTEREST?
In this second part of the review the current literature focusing
on medications used for the treatment of acute mania is critically
reviewed.
LITHIUM
Numerous controlled studies have clearly established the supe-
riority of lithium as compared to placebo in acute mania. As a
consequence, since the 1990s, studies designed to evaluate newer
medications have used lithium as the gold standard treatment
(Bowden et al., 1994). A slower onset of action of lithium as com-
pared to other medications has been discussed (Bowden et al.,
1994). Most of the placebo-controlled studies varied as regard to
dosage, serum levels, and rapidity of dosage titration of lithium,
making it difficult to establish the precise time to onset of lithium
antimanic action. Nonetheless, there is little doubt that lithium
is as effective as other antimanic agents over a 3-week period,
while some studies have even reported a quicker onset of action
(10 days).
Actually, the largest randomized double-blind study of lithium
versus placebo in acutely manic patients was designed to study
the benefits of divalproex (valproate) in the treatment of acute
mania, with lithium and placebo-treated groups serving as con-
trols (Bowden et al., 1994; Swann et al., 1997, 2000). In this study,
nearly 50% of respectively the lithium-treated patients and the
valproate-treated group were improved (i.e., >50% reduction of
YMRS scores) during the 3-week trial period as compared with
about 25% in the placebo group. Nearly half of the patients had a
previous history of poor response to lithium, which predicted the
differential response observed in this trial. Thus, among the prior
lithium responders who were receiving lithium in this trial, there
was a 15-point mean reduction in YMRS scores (60% improve-
ment), compared with only a one-point mean improvement in the
previously lithium non-responders (Bowden et al., 1994). Among
the prior lithium responders who were randomized to valproate,
by contrast, there was only a 27% improvement, compared with
the 60% improvement observed with lithium.
A meta-analysis of six randomized controlled trials using
lithium for the treatment of acute mania reported an overall stan-
dardized effect size of 0.40 (95% CI: 0.28–0.53) and an overall
numbers-needed-to treat patients for response of 6 (95% CI: 4–13;
Storosum et al., 2007).
Plasma levels for lithium in recent controlled studies were
usually in the range between 0.6 and 1.3 mmol/l.
ANTICONVULSANTS
The use of anticonvulsant agents for the treatment of bipolar dis-
orders was a watershed event in psychiatry in the late twentieth
century. The effectiveness of some anticonvulsants in patients who
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did not respond adequately or who could not tolerate lithium
has made these drugs a welcome addition to the armamentar-
ium. Controlled trials have shown that both valproate and carba-
mazepine were more effective than placebo, and as noted above,
as effective as lithium for the treatment of acute mania (Post et al.,
1986; Small et al., 1991; Bowden et al., 1994, 2006; Weisler et al.,
2004, 2005).
In contrast,placebo-controlled data are negative concerning the
acute manic phase for gabapentin and topiramate (Fountoulakis
et al., 2012).
Carbamazepine
Starting in the 1970s, a number of studies have shown that car-
bamazepine was superior to placebo, although not necessarily
equivalent to lithium in the short term treatment of mania. Okuma
et al. (1990) have conducted a double-blind placebo-controlled
study including manic patients who were receiving antipsychotic
treatment without substantial benefit. In half of the 105 patients,
200–400 mg/day of carbamazepine was added to haloperidol, and
in the other half, lithium was added to haloperidol (mean lithium
plasma concentration: 0.46 meq/l). At endpoint, all patients were
moderately to markedly improved. Since all patients were receiv-
ing a mood stabilizer in combination with haloperidol, it remains
unclear how much of the improvement observed was due to the
adjunctive mood stabilizers or to haloperidol. Small et al. (1991)
conducted a 8-week double-blind comparison study of carba-
mazepine and lithium in 52 hospitalized acutely manic patients.
They have found that both drugs were equally effective in reducing
manic symptoms (as assessed by YMRS scores), a conclusion sup-
ported by a later meta-analysis (Emilien et al., 1996). The first large
randomized placebo-controlled mania study has shown significant
superiority of carbamazepine as compared to placebo in the treat-
ment of acute mania (Weisler et al., 2004, 2005). However, some
tolerability issues with rapid titration and its interaction potential
with numerous psychiatric and non-psychiatric medications limit
its use (Grunze et al., 2009).
Conclusive evidence is lacking for oxcarbazepine (Grunze et al.,
2009).
Valproate
Valproate is a common generic name used for different prepa-
rations (valproic acid, sodium valproate, divalproate, divalproex
sodium, and valpromide). Only valproic acid reaches and pene-
trates the blood brain barrier. The French psychiatrist Lambert first
reported a possible role of valproate in the treatment of bipolar
disorders during the first clinical trials in patients with epilepsy in
the 1960s (Lambert et al., 1966). Many years later, Calabrese and
Delucchi (1990) reported that this compound appeared to have
marked effect in mania. They also noted that most of the patients
(63%) showing a good clinical improvement with valproate had
failed to improve previously on lithium, carbamazepine, or both.
Randomized, placebo-controlled studies have compared val-
proate with placebo and with lithium. In the first study (Pope
et al., 1991), 17 patients were randomized to divalproex and
19 to placebo. The divalproex-treated patients have shown a
median improvement of 54% (YMRS scale), versus only 5% in the
placebo group. Similar benefits were observed using the Global
Assessment of Social Scale (GAS) and the Brief Psychiatric Rating
Scale (BPRS). However, in the divalproex group, only 24% of the
patients completed the 3-week study versus 21% in the placebo
group.
In the largest placebo-controlled study of acute mania con-
ducted to date, 179 patients with acute mania were receiving dival-
proex, lithium, or placebo for 21 days (Bowden et al., 1994) and,
as previously outlined in Pope’ study, a large number of patients
failed to complete this study. The patients had been separated into
four different groups based on a factorial approach to mania, using
different clinical and nursing evaluation scales, namely groups of
patients with depressive or irritable (hostile) or psychotic or con-
ventional (hyperactivity) forms of the disease. The study results
show that the depressive forms of the disorder have a poor response
to the two treatments assessed whereas the psychotic and conven-
tional responded well to treatment. The irritable forms had a better
response to divalproate than to lithium. This study thus revealed
a significant difference in divalproate compared with placebo
as regards impulsiveness and hostility (unlike lithium) whereas
lithium and divalproate were both significantly more effective than
placebo in terms of the hyperactive component of mania.
Plasma levels of 75–99 mg/l or 520–690 mmol/l seem to be asso-
ciated with the best efficacy/tolerability ratio for valproate and
caution should be used in women of child-bearing age (Grunze
et al., 2009).
Lamotrigine
Lamotrigine is an anticonvulsant with sodium channel blocking
activity similar to that of carbamazepine and phenytoin. Case
reports and open studies have suggested some efficacy for lamot-
rigine in the treatment of mania, but this result was not confirmed
in controlled studies. A small (30 subjects) 4-week randomized
controlled trial has compared lamotrigine with lithium in the
treatment of hospitalized manic patients (Ichim et al., 2000).
Both lithium and lamotrigine groups shared similar reductions
of YMRS scores, but the absence of a placebo group renders the
results of this study inconclusive. Other controlled studies con-
ducted in manic patients have found no significant differences
between lamotrigine and placebo (Frye et al., 2000).
ANTIPSYCHOTICS
During the past decade the treatment of mania has significantly
changed with the introduction of atypical antipsychotics. Among
the atypical antipsychotics, olanzapine, and risperidone have been
most extensively studied. Nivoli et al. (2011), in their recent meta-
analysis, have reported that monotherapy with atypical antipsy-
chotics is recommended in all guidelines as a first-line choice
in the treatment of acute mania because of their sedative prop-
erties and their short term side-effect profile. Although not yet
proved in meta-analysis, several trials have shown that atypical
antipsychotics have also a lower risk of switch to depression.
Aripiprazole
This atypical antipsychotic has a pharmacodynamic profile that
distinguishes it from other antipsychotics by being a partial agonist
rather than an antagonist of dopamine D2 receptors. Aripiprazole
has proven to be an effective medication for the acute treatment
of manic and mixed episodes.
www.frontiersin.org January 2013 | Volume 4 | Article 4 | 5
Bourin and Thibaut Treatment of acute bipolar mania
Keck et al. (2003) have conducted a 3-week double-blind,
placebo-controlled study using aripiprazole in the treatment of
mania in 262 hospitalized patients. They have found a 40%
response rate (defined as a decrease of 50% or more of YMRS
scores) compared with 19% in the placebo group. These find-
ings were subsequently replicated in a second multicentre 3-week
study involving 272 manic patients (135 on aripiprazole, 137 on
placebo). On the basis of these results, the FDA has approved
aripiprazole for the treatment of acute mania.
Vieta et al. (2005) have conducted a double-blind, controlled
study of aripiprazole and haloperidol in patients with bipolar I
disorder experiencing acute manic or mixed episodes. Patients
(n= 347) were randomized to receive aripiprazole or haloperidol
in this 12-week, multicentre study. The primary outcome mea-
sure was the number of patients in response (greater, similar 50%
improvement from baseline in YMRS score) and receiving therapy
at week 12. At week 12, significantly more patients taking aripipra-
zole (49.7%) were in response and receiving therapy compared
with those taking haloperidol (28.4%; P < 0.001). Continuation
rates differed markedly between treatments (week 12: aripiprazole,
50.9%; haloperidol, 29.1%). Extrapyramidal adverse events were
more frequent with haloperidol than aripiprazole (62.7 versus
24.0%). Aripiprazole showed superior levels of response and tol-
erability to haloperidol in the treatment of an acute manic episode
for up to 12 weeks.
Asenapine
Asenapine is a novel pharmacological agent available in sublin-
gual formulations that binds with high affinity and specificity to
numerous dopamine, serotonin, noradrenaline (norepinephrine),
and histamine receptor subtypes (Weber and McCormack, 2009).
In two large (n= 480),well designed,3-week trials conducted in
adult patients with bipolar I disorder, asenapine used in monother-
apy was significantly more effective than placebo in improving
manic symptoms as assessed using the YMRS total score (pri-
mary endpoint) and the CGI-BP. Significant differences between
the asenapine and placebo groups were observed after 2 days of
treatment (Chwieduk and Scott, 2011). In one trial, both response
and remission rates exceeded those observed in the placebo group.
In a 9-week extension study, comparing asenapine and olanza-
pine, including completers from these monotherapy trials, there
were no significant differences between asenapine and olanzapine
using the MADRS scores, the CGI-BP mania severity scores, the
YMRS response rates, and the YMRS remission rates during the
extension phase. In the extension study, the efficacy of asenapine
in monotherapy appeared to be maintained during 40 weeks (total
treatment duration of 52 weeks). In a 12-week trial using asenap-
ine as an adjunctive therapy to lithium or valproate (Szegedi et al.,
2012), asenapine was more effective than placebo in improving
manic symptoms, based on the YMRS total score at week 3 (pri-
mary endpoint). Most of the adverse events associated with ase-
napine were of mild to moderate severity, with less than 7% of the
patients receiving asenapine experiencing serious adverse events
(versus 7% with placebo). In a pooled analysis of the monotherapy
trials, the most common adverse events reported during the acute
phase of asenapine treatment for bipolar mania were: somnolence,
dizziness, extrapyramidal symptoms (EPS; other than akathisia),
and increased body weight. These side effects were occurring in less
than 5% of the patients which was twice the incidence observed
in the placebo group. The same side effects were observed during
longer term monotherapy with asenapine without any worsening
of the severity of EPSs. Asenapine seems to have minimal effects
on plasma glucose or lipid measurements and prolactin levels over
both short and longer term treatment periods, and had little pro-
arrhythmogenic potential. However, further studies using active
comparators as well as longer term tolerability and safety data are
required. In the meantime, asenapine is a further option for the
management of manic and/or mixed symptoms in patients with
bipolar I disorder.
Haloperidol
Haloperidol is an old classical antipsychotic agent that remains
widely used. In Europe, it was considered as the gold standard
treatment for acute mania during decades. In recent and well
designed studies, this agent has demonstrated acute antimanic
efficacy. Prophylactic utility of this agent has not been adequately
examined in long term studies.
There was some evidence that haloperidol was more effi-
cient than placebo in terms of reduction of manic and psy-
chotic symptom scores, when used both as monotherapy and
as add-on treatment to lithium or valproate. There was no evi-
dence of any difference in terms of efficacy between haloperidol
and risperidone, olanzapine, valproate, carbamazepine, sultopride,
or zuclopentixol. There was a statistically significant difference
between haloperidol and aripiprazole in favor of the latter. No
comparative efficacy data were reported with quetiapine, lithium,
or chlorpromazine.
To assess the efficacy of haloperidol in the treatment of mania,
Cipriani et al. (2006), have completed a meta-analysis of random-
ized trials comparing haloperidol with placebo or other active
compounds in the treatment of acute manic or mixed episodes
in patients with bipolar disorder either as monotherapy or as an
add-on therapy. Fifteen trials involving 2022 people were included.
Compared to placebo, haloperidol was more effective in reducing
manic symptoms, both as monotherapy [Weighted Mean Differ-
ence (WMD) 5.85 (95% CI: 4–7.69)] and as adjunctive treatment
as compared to lithium or valproate [WMD 5.20 (95% CI: 1.14–
9.26)]. Haloperidol was significantly less effective as compared to
aripiprazole [RR: 1.45 (95% CI: 1.22–1.73)]. No significant differ-
ences were observed between haloperidol, risperidone, olanzapine,
carbamazepine, or valproate. Compared with placebo, a statisti-
cally significant difference in favor of haloperidol was reported
in failure to complete treatment [RR: 0.74 (95% CI: 0.57–0.96)].
Haloperidol was associated with less weight gain than olanzapine
[RR: 0.28 (95% CI: 0.12–0.67)], but with a higher incidence of
tremor [RR: 3.01 (95% CI: 1.55–5.84)] and other movement dis-
orders. Haloperidol caused more EPS than valproate but no differ-
ence was found between haloperidol and lithium, carbamazepine,
or risperidone in terms of side effects profile.
The authors concluded that there is some evidence that
haloperidol is an effective treatment for acute mania. From the
limited data available, there was no difference in overall efficacy
of treatment between haloperidol and olanzapine or risperidone.
Some evidence suggests that haloperidol could be less effective
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than aripiprazole. Concerning tolerability, clinicians, and patients
should be aware of the differing side effect profiles of these com-
pounds. Typical antipsychotics may be more likely to induce
depressive symptoms as compared to atypicals (Tohen et al., 2003).
In addition, the use of haloperidol is clearly limited by its propen-
sity to induce acute EPSs and later on tardive dyskinesia. Natural-
istic data have suggested that bipolar patients may be at higher risk
for these side effects as compared to schizophrenic patients (Keck
et al., 2000).
Olanzapine
This atypical agent has been shown to be superior to placebo in
several randomized, double-blind comparisons in the treatment
of acutely manic patients. Olanzapine at a dose of 5–20 mg/day
resulted in substantially greater improvement as compared to
placebo-treated subjects in a 3-week study (Tohen et al., 1999). The
olanzapine treated patients response rate (defined as a reduction
in YMRS score) was 48%, compared with 24% in the placebo-
treated group. The difference favoring olanzapine was significant
after the third week of the study. A second randomized, placebo-
controlled study yielded similar results, except for the difference
in efficacy between olanzapine and placebo which appeared after
only 1 week of treatment and was sustained throughout the dura-
tion of the trial (Tohen et al., 2000). In a 3-week randomized,
double-blind study comparing olanzapine (5–20 mg/day, mean
dose 17.4 mg/day) with divalproex (500–2500 mg/day, mean dose
1 401 mg/day, mean blood level of 82 mg/ml) for the treatment of
acute mania (Tohen et al., 2002), a slight but significant advantage
was observed for olanzapine over divalproex. Clinical improve-
ment was evaluated using the percentage of patients achieving a
greater than 50% decrease in YMRS scores, remission was evalu-
ated using the percentage of patients with a YMRS score of 12 or
lower. A 44-week double-blind extension of this study found that
after only 15 weeks of treatment, the efficacy of valproate was sim-
ilar to that of olanzapine (Zajecka et al., 2002; Tohen et al., 2003).
By contrast, Zajecka has reported similar efficacies for olanzap-
ine and valproate in a 12-week randomized, double-blind study
involving 120 patients with acute mania. As compared with the
Lilly funded Tohen’ study, the Abbott-founded Zajeka’ study has
used a lower dose of olanzapine (mean dose: 14.7 mg/day) and a
higher dose of valproate (mean dose: 2115 mg/day compared to
1401 in the previous study) which might explained the different
results observed between the two studies. In both studies, patients
receiving olanzapine experienced significantly more side effects,
especially somnolence and weight gain, than those in the valproate
group. Compared with lithium, olanzapine has shown a greater
efficacy as compared to lithium in a 4-week trial but olanzapine
was associated with more frequent side effects which may limit its
use (Niufan et al., 2008). A large pan-European naturalistic mania
study has confirmed the efficacy of olanzapine as monotherapy or
in combination with other medications in a broad spectrum of
manic patients (Vieta et al., 2008). The most worrisome adverse
effects of olanzapine are metabolic.
Quetiapine
Several case reports (Dunayevich and Strakowski, 2000), and ret-
rospective case series have suggested a useful role for the atypical
antipsychotic quetiapine when used as an adjunctive treatment for
mania.
Two large international multicentre randomized, double-blind,
placebo-controlled trials have evaluated the efficacy of quetiapine
monotherapy (400–800 mg/day) in hospitalized manic patients. In
the first one (Bowden et al., 2005), 302 patients were randomized
to quetiapine (n= 1007), lithium (n= 98), or placebo (n= 95). At
week 3, the decrease in YMRS scores was significantly greater for
both drugs compared with placebo (P < 0,001); the extent of the
improvement was virtually identical for the two drugs. The other
study McIntyre et al. (2005) was of the same size using the same
design, except for the active comparator which was haloperidol; the
results obtained were similar, except for the effect of haloperidol
at week 3 which was slightly more robust than that of quetiapine.
In both studies, quetiapine has shown significantly greater efficacy
than placebo.
Two large randomized, placebo-controlled trials (Sachs et al.,
2004; Yatham et al., 2004) have examined the efficacy of adjunc-
tive quetiapine in 402 hospitalized manic patients who were still
substantially symptomatic (YMRS scores ≥20) after a minimum
of 7 days of lithium or divalproex treatment. In both studies, the
adjunction of quetiapine was associated with a significantly greater
improvement as compared to mood stabilizer alone.
Regarding antipsychotics, it is important to note that patients
were included in these adjunctive studies after at best a partial
response to at least 1 week of previous treatment with mood
stabilizers alone; thus the generalization of these results is limited.
The drop-out rates observed in these controlled studies due to
side effects were comparable to placebo drop-outs.
Risperidone
In open studies conducted in manic patients, Tohen et al. (1996)
have reported a 50% or greater reduction in manic symptoms
in 10 out of 12 patients when risperidone was added to lithium.
Keck et al. (1995), have studied a mixed group of patients receiv-
ing risperidone, noting that all nine bipolar patients with mania
showed moderate to marked improvement when risperidone was
added to a mood-stabilizing regimen consisting of lithium, val-
proate, or carbamazepine. Ghaemi and Sachs (1997) have found
that 9 of 14 bipolar patients, most with mania or mixed states,
were significantly improved by the addition of small doses of
risperidone (<3 mg/day) to mood stabilizers.
A randomized, double-blind study of risperidone in com-
bination with lithium, carbamazepine, or valproate showed a
significantly faster decline in YMRS scores in patients receiving
risperidone in addition to a mood stabilizer. The mean risperidone
dose in this study was 4 mg/day (Yatham et al., 2003). In another
prospective double-blind, placebo-controlled trial of risperidone
as an adjunctive treatment for mania (to lithium or valproate,
when the response was not adequate to previous treatment with
these mood stabilizers), Sachs et al. (2002), have observed a greater
improvement in YMRS scores with risperidone as compared to
placebo at the end of the first, second, and third weeks respectively.
Similar findings were reported by Yatham et al. (2004), who ran-
domly added risperidone (n= 75) or placebo (n= 75) to lithium
or valproate, with a significantly greater reduction in YMRS scores
when combined treatment was used.
www.frontiersin.org January 2013 | Volume 4 | Article 4 | 7
Bourin and Thibaut Treatment of acute bipolar mania
A 3-week-randomized study was conducted by Hirschfeld et al.
(1999) in 134 manic patients receiving risperidone (mean dose
of 4.1 mg/day) as compared to placebo (15 patients). The YMRS
scores were significantly decreased in the risperidone group as early
as the third day: 43% of those randomized to risperidone met the
response criteria at endpoint versus only 24% in the placebo group.
Remission rates (reduction of YMRS scores≤12) were respectively
of 38% for risperidone versus 24% for placebo.
In a randomized, double-blind trial of risperidone monother-
apy, 45 manic patients were receiving risperidone (6 mg/day),
haloperidol (10 mg/day), or lithium (800–1 200 mg/day) during a
3-week trial (Tohen et al., 2003). There were no differences in treat-
ment outcomes among the three groups with a mean improvement
of about 50–60% on the YMRS, as well as substantial improvement
on general psychopathology and functioning scales (Segal et al.,
1998).
Finally, in a recent randomized double-blind comparison study,
risperidone and olanzapine has shown similar antimanic efficacy
(Perlis et al., 2006). Overdosing of risperidone (>6 mg/day) should
be avoided as this clearly impacts effectiveness due to EPSs and
prolactin elevation (Grunze et al., 2009).
Ziprasidone
Ziprasidone monotherapy was tested for antimanic efficacy in
three double-blind placebo-controlled studies which confirmed
its antimanic efficacy. Despite of its good metabolic profile, due to
the fear of potential cardiac toxicity, ziprasidone is not available
in some countries and its use is restricted in others (Grunze et al.,
2009).
The antimanic efficacy of clozapine, zotepine, and paliperidone
(a risperidone metabolite) needs to be confirmed.
Intramuscular formulations of aripiprazole and olanzapine
have shown efficacy in agitated patients suffering from acute
mania.
CONCLUSION
All the current guidelines agree on first treating manic/hypomanic
or mixed episodes with lithium, valproate, or some atypical
antipsychotics as monotherapy, in order to minimize side effects.
Clinical studies suggest that carbamazepine is weaker than lithium
and that sodium valproate is superior to lithium in reducing
symptoms of mania. Sodium valproate is used in patients resis-
tant to lithium treatment. Among the atypical antipsychotics,
olanzapine, and risperidone have been most extensively stud-
ied. In our opinion, atypical antipsychotics are very important
in the treatment of mania because their sedative effects may be
desirable in the short term treatment of mania. Yet aripipra-
zole at 30 mg alone showed efficacy even though it is not so
sedating.
Combinations (atypical antipsychotics plus lithium or val-
proate) should be reserved for severe mania as first-line choice
or as a second-line choice in mild or moderate mania in which a
first-line medication has failed. In a recent meta-analysis of ran-
domized controlled studies comparing one active antimanic drug
with another one or with placebo including combination and aug-
mentation studies, risperidone, olanzapine, and haloperidol have
shown the best efficacy profile in the treatment of acute mania
while lamotrigine, topiramate, and gabapentin were not signifi-
cantly better than placebo (Cipriani et al., 2011). In another meta-
analysis of co-therapy and monotherapy in acute bipolar mania,
Smith et al. (2007) analyzed 8 RCTs including 1124 patients and
found that significant reductions in mania (>50% reduction from
baseline at YMRS scores) were shown for haloperidol, olanzapine,
risperidone, and quetiapine as co-therapy combined with a mood
stabilizer even if combination was less well tolerated as compared
with monotherapy. Goodwin et al. (2009), during the ECNP con-
sensus meeting, suggested that conventional two-arm trial designs
could benefit form adding a third antipsychotic monotherapy arm
in order to improve data from studies which compare and quantify
the efficacy of antipsychotics in monotherapy or in combination.
In reality, less than 10% of acutely manic patients receive
monotherapy, the number of medications in manic patients is at
least two (Haro et al., 2010). Licht et al. (1997) has estimated that
less than 20% of a screened naturalistic patient cohort fulfils all
inclusion criteria for entering a randomized controlled trial (Licht
et al., 1997).
In the case of carbamazepine treatment, no combination
with other agents is recommended because of potential inter-
actions. The recommendations suggest to change the ongoing
carbamazepine treatment with another first-line treatment.
All guidelines agree on stopping the ongoing antidepressant
medication during a manic/mixed episode (Nivoli et al., 2011).
Despite this clear recommandation, clinicians continue to pre-
scribe antidepressant medications in at least 15% of the manic
and mixed patients (Rosa et al., 2010).
Most guidelines recommend continuation of treatment for 6–
12 months after remission from acute mania however controlled
studies are lacking except for lithium, olanzapine, and aripipra-
zole but data supporting this recommendation for these latter
compounds are only grade B (WFSBP guidelines, Grunze et al.,
2009). Which drug should be discontinued first in case of com-
bination therapy or how doses may be reduced after remission
remains based on clinical experience. In addition and despite the
lack of strong data, some guidelines recommend that all patients
should be offered maintenance treatment after an acute episode,
the WFSBP recommends to consider the overall efficacy and tol-
erability of the medications in long term treatment in selection of
a drug or a regimen for acute treatment of mania.
The question of which is the best strategy to face partial
response is unanswered by the current guidelines. Evidence is lack-
ing about when to stop a medication if the first choice treatment is
inefficacious or leads to a partial response or when to add another
medication (e.g., an atypical antipsychotic to the mood stabilizer).
In addition,usually a 50% reduction in theYMRS or MRS is used as
a response criterion but clear and valid definitions and assessments
of partial response to treatment are needed.
In clinical practice, severity of mania and speed of onset of
action are the primary arguments in first choice treatment of an
acute manic episode.
In Europe, haloperidol remains a gold standard even if this
drug is not registered in the treatment of acute mania. Lithium
would be the ideal comparator except for the cases where mania
is recurring in patients already receiving lithium for maintenance
treatment with adequate dosage.
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Direct comparative trials between atypical antipsychotics are
still limited except for the comparison between olanzapine and
risperidone. Others are either inconclusive, or not powered for
comparison except for three studies showing that haloperidol is
more powerful in the short term treatment of acute mania than
olanzapine, quetiapine (Grunze et al., 2009).
Finally, so far, no psychological intervention has shown efficacy
in controlled studies in comparison to a “placebo” intervention in
mania (Gutierrez and Scott, 2004).
Rational therapeutic development in bipolar is hampered by
a lack of pathophysiological model. However, there is a wealth
of converging data on the role of dopamine in bipolar disorder.
Pharmacological models suggest a role of increased dopaminer-
gic drive in mania and the converse in depression. In Parkinson’s
disease, administration of high-dose dopamine precursors can
produce a “maniform” picture, which switches into a depressive
analog on withdrawal. It is possible that in bipolar disorder there
is a cyclical process, where increased dopaminergic transmission
in mania leads to a secondary down regulation of dopamin-
ergic receptor sensitivity over time. This may lead to a period
of decreased dopaminergic transmission, corresponding with the
depressive phase, and the repetition of the cycle. This model, if ver-
ified, may have implications for rational drug development (Berk
et al., 2007).
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